Roquette Continues Momentum with Pharmaceutical Investments

Lestrem (France), 24th August 2017 – Roquette, a global leader in innovative plant-based pharmaceutical ingredients, continues to be on the move by opening a new facility in Singapore.

Over the last few months Roquette has made several major investment announcements that will position the company for future growth. The addition of a new Pharmaceutical R&D and Customer Technical Service facility in Singapore will complement Roquette’s deep expertise in formulation and application science, giving customers throughout Asia the ability to receive localized project support and in-depth application training.

This state-of-the-art facility will be home to world-class technical teams who will partner with customers to develop new innovations and formulations in the areas of pharmaceutical excipients and drug delivery systems for oral dosage forms and injectables. The over 1,100 square meter space is located in Biopolis, an international research and development hub for fast-growing areas in Asia Pacific such as biomedical sciences, bioengineering, medical technology (MedTech), personal care, food and nutrition. Capabilities include the development of new products and new applications for existing products as well as pre-clinical research. Additionally, this facility is equipped for physical and chemical characterization of materials, support for pharmaceutical customers with prototypes, and formulation and process development. 

This announcement follows the March Biopharma segment launch which added three new brands to the portfolio and the acquisition of Itacel, Blanver’s excipient division announced in May that will enable Roquette to expand its footprint in North America, Brazil and Latin America.

The new R&D and CTS facility will be a key asset to support the Roquette’s Pharma Business Unit growth ambitions, and there are expansion plans for a Biopharma lab. This will serve as Roquette’s Global Biopharma Center of Excellence. Stay tuned for more information.